Express the truth to gain the trust

Key Topics

MVD: Multivessel disease

The first SYNTAX results have been released, and along with a selection of presentations from EuroPCR, provide us with the opportunity to understand the complexity of MVD.

The SYNTAX trial

Read our interview with Patrick W. Serruys here.

Access the slides on the ESC website here.

More about SYNTAX

A Post-ESC/Pre-SYNTAX LM Perspective: Should DES Be Used in Patients with Unprotected Left Main Disease? Data Synthesis and Clinical Recommendations
Speaker: M.-C. Morice

The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study
Speaker: M.-C. Morice

Left Main: A balanced approach customized to the patient and lesion makes the most sense
Speaker: M.-C. Morice

Clinical video
A typical "SYNTAX" patient treated with PCI at the Clinique Pasteur
A live case from the Clinique Pasteur, Toulouse (60 min.).
Webcasts
Your approach in the debate CABG-PCI:: results from a web based survey
Frontiers in percutaneous coronary intervention (4 min.)
Speaker: W. Wijns
Not all MVD patients look alike: B De Bruyne help us evaluate their heterogeneity to have better understanding of recent trials
Heterogeneity of patients with multivessel disease: implications for revascularisation strategies (14 min.).
Speaker: B. de Bruyne
The state of the art in Coronary Artery Bypass Grafting (CABG)
Contemporary bypass surgery: a glossary for the cardiologist (24 min.).
Speaker: F.W. Mohr
Lectures

The surgical techniques for CABG

How do surgical techniques affect the clinical outcomes?
Speaker: D. Taggart

Off pump CABG

Off pump coronary surgery - where are we now?
Speaker: G. Angelini

What's new about redux CABG?

Repeat bypass surgery. Is it time for a re-evaluation?
Speaker: D. Steinbruechel

The CABG results in registries

Patients status and current surgical practice: cardiac surgery registries (Society of Thoracic Surgeons, European Association for Cardio-thoracic Surgery)
Speaker: F.W. Mohr

The specificity of MVD in diabetic

Managing the diabetic patient
Speaker: B. Reimers

Multivessel disease and the diabetic patient
Speaker: W. Desmet

How to approach MVD in acute MI setting?

Multivessel disease in primary PCI
Speaker: S. Worthley

Which patients do interventionalists send to surgeons?

As an interventionalist, for which patient would I advise surgery?
Speaker: F. Mauri

Coronary artery bypass surgery is the definitive treatment
Speaker: R. Seabra-Gomes

The CABG-PCI debate: the cost-effectiveness approach

Benefit and risks of multilesion, multivessel percutaneous coronary intervention using drug-eluting stents, including cost effectiveness considerations
Speaker: D.J. Cohen

The CABG-PCI debate: a quest for a consensus

A consensus
Speaker: E. Eeckhout

EuroIntervention related content

Understand the SYNTAX score: The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease

Three-year follow-up of the ARTS-II – Sirolimus-eluting stents for the treatment of patients with multivessel coronary artery disease

Short- and long- term health related quality-of-life and anginal status after randomisation to coronary stenting versus bypass surgery for the treatment of multivessel disease: results of the Arterial Revascularisation Therapy Study (ARTS)

Diabetic patients treated for unprotected left main coronary artery disease with drug eluting stents: a 3-year clinical outcome study. The Diabetes and Drug Eluting stent for LeFT main registry (D-DELFT)

One year results of a new in situ length-adjustable stent platform with a biodegradable Biolimus A9 eluting polymer: results of the CUSTOM-II trial

Elective implantation of sirolimus-eluting stents for bifurcated and non-bifurcated unprotected left main coronary artery lesions: clinical outcomes at one year.

To consult other topics, click here.


Back